Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 8c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $4.48 -1.75%
EPS Growth %: -16.7%
Financial Fact:
Product sales: 38.48M
Today's EPS Names:
FRSB, DGICA, UXIN, More
EPS Growth %: -16.7%
Financial Fact:
Product sales: 38.48M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of ($0.01), $0.08 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $38.24 million versus the consensus estimate of $38.39 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- Capital One Financial (COF) Misses Q1 EPS by 4c
- Atlassian (TEAM) Tops Q3 EPS by 30c, provides guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
